Becton Dickinson Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/15/2026)
| Balance Sheet | Total Assets | 55,325,000,000.00 | ROE | 45.89 % |
| Balance Sheet | Total Equity | 25,390,000,000.00 | ROA | 3.03 % |
| Cashflow | Capital Expenditures | -760,000,000.00 | P/FCF | 25.84 |
| Cashflow | Free Cash Flow | 2,670,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 3,430,000,000.00 | P/CF | 20.11 |
| Income | Earnings per Share (diluted) | 3.60 | Div. Yield | 1.36 % |
| Income | Net Income | 1,678,000,000.00 | P/E | 52.47 |
| Income | Shares Outstanding | 464,552,208.00 | P/B | 2.72 |
| Income | Total Revenue | 21,839,000,000.00 | P/S | 3.16 |
Ratios calculated on: 10/14/2026
Company Description
Becton Dickinson and Co, formerly Becton Dickinson & Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company' s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bd.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more